Neuron23 Inc.

Biohaven Ltd. is plunking down $20m up front and in a licensing deal worth up to $950m in milestones fees to access a Chinese biotech company’s preclinical dual inhibitor of TYK2 and JAK1 in the hope

Neuron23 Inc. aims to take two small molecule drug candidates for neurological diseases into the clinic during the next two years, with $100m from a series C venture capital round that the company an

Biopharmaceutical companies developing therapies for neurological diseases are in the midst of a boom, not only in terms of novel approaches to treating intractable diseases but also in terms of attra